Jörg L.
- Country
- Germany
- Department
- Pädiatrische Onkologie und Hämatologie
Research Overview
- International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
- International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
- Reduced‑intensity post‑induction chemotherapy plus blinatumomab versus standard post‑induction therapy in pediatric standard‑risk B‑ALL (AIEOP‑BFM ALL 2025)
Data & Insights
Has run more than one trial at 217 of 289 partner sites.
Specializations
Leukemia Research
This investigator specializes in treating various forms of acute leukemia, with particular emphasis on pediatric and adolescent populations. Their research encompasses Philadelphia chromosome-positive acute lymphoblastic leukemia and acute myeloid leukemia.
- Standard and High-Risk ALL Treatment Protocols
- Myeloid Leukemia in Down Syndrome
- B-cell Leukemia Management
Areas of focus include innovative treatment approaches and immunotherapy integration in leukemia care.
Lymphoma Studies
The investigator conducts research in various lymphoma subtypes, particularly focusing on anaplastic large cell lymphoma and lymphoblastic lymphoma in young patients.
- ALK-positive ALCL Treatment
- B-cell Lymphoma Protocols
- Lymphoblastic Lymphoma Management
Treatment approaches include targeted therapies and novel therapeutic combinations.
Solid Tumor Research
The investigator's work extends to solid tumors, with specialized focus on Ewing sarcoma and renal tumors in pediatric patients.
- Stage IV Renal Tumor Treatment
- Ewing Sarcoma Management
- Metastatic Disease Protocols
Research includes optimization of treatment strategies for both localized and metastatic disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.